HBM Holdings-B (02142) Forms Strategic Alliance with China National Pharmaceutical Group to Establish Joint Innovation Body

Stock News07-27

HBM Holdings-B (02142) has announced the signing of a strategic cooperation agreement with China National Pharmaceutical Group (Sinopharm) to create the Sinopharm-HBM Innovation Consortium. This partnership will focus on research and development in the field of innovative biologics, with a strategic emphasis on therapeutic areas such as oncology and immuno-inflammatory diseases.

Under the terms of the agreement, the collaboration will span the entire lifecycle of innovative biologic drug development. HBM Holdings-B will leverage its globally leading fully human antibody technology platform, Harbour Mice®, along with its AI-enhanced research capabilities, to jointly conduct the discovery and optimization of candidate antibody molecules with Sinopharm. This includes, but is not limited to, target validation, lead antibody discovery and optimization, antibody configuration design, and antibody engineering.

Sinopharm will contribute its expertise in clinical trials, large-scale production, and commercialization. Its responsibilities will include developing commercial-scale process technologies, producing materials for clinical trials, and commercializing the products resulting from the collaboration. Both parties will share research and development costs and product rights according to agreed-upon terms.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148016584?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 17:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148016584","market":"fut","top_or_hot":-1,"title":"HBM Holdings-B (02142) Forms Strategic Alliance with China National Pharmaceutical Group to Establish Joint Innovation Body","media":"Stock News","content":"<p><b>HBM Holdings-B (02142)</b> has announced the signing of a strategic cooperation agreement with China National Pharmaceutical Group (Sinopharm) to create the Sinopharm-HBM Innovation Consortium. This partnership will focus on research and development in the field of innovative biologics, with a strategic emphasis on therapeutic areas such as oncology and immuno-inflammatory diseases.<br><br>Under the terms of the agreement, the collaboration will span the entire lifecycle of innovative biologic drug development. <b>HBM Holdings-B</b> will leverage its globally leading fully human antibody technology platform, Harbour Mice®, along with its AI-enhanced research capabilities, to jointly conduct the discovery and optimization of candidate antibody molecules with Sinopharm. This includes, but is not limited to, target validation, lead antibody discovery and optimization, antibody configuration design, and antibody engineering.<br><br>Sinopharm will contribute its expertise in clinical trials, large-scale production, and commercialization. Its responsibilities will include developing commercial-scale process technologies, producing materials for clinical trials, and commercializing the products resulting from the collaboration. Both parties will share research and development costs and product rights according to agreed-upon terms.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings-B (02142) Forms Strategic Alliance with China National Pharmaceutical Group to Establish Joint Innovation Body</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings-B (02142) Forms Strategic Alliance with China National Pharmaceutical Group to Establish Joint Innovation Body\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-27 17:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>HBM Holdings-B (02142)</b> has announced the signing of a strategic cooperation agreement with China National Pharmaceutical Group (Sinopharm) to create the Sinopharm-HBM Innovation Consortium. This partnership will focus on research and development in the field of innovative biologics, with a strategic emphasis on therapeutic areas such as oncology and immuno-inflammatory diseases.<br><br>Under the terms of the agreement, the collaboration will span the entire lifecycle of innovative biologic drug development. <b>HBM Holdings-B</b> will leverage its globally leading fully human antibody technology platform, Harbour Mice®, along with its AI-enhanced research capabilities, to jointly conduct the discovery and optimization of candidate antibody molecules with Sinopharm. This includes, but is not limited to, target validation, lead antibody discovery and optimization, antibody configuration design, and antibody engineering.<br><br>Sinopharm will contribute its expertise in clinical trials, large-scale production, and commercialization. Its responsibilities will include developing commercial-scale process technologies, producing materials for clinical trials, and commercializing the products resulting from the collaboration. Both parties will share research and development costs and product rights according to agreed-upon terms.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1148016584","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148016584","pubTimestamp":1785143347,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HBM Holdings-B (02142) has announced the signing of a strategic cooperation agreement with China National Pharmaceutical Group (Sinopharm) to create the Sinopharm-HBM Innovation Consortium. This...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","02142":"和铂医药-B","BK1583":"高瓴概念"},"translate_title":"HBM Holdings-B(02142)与中国医药集团结成战略联盟，成立联合创新机构","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"HBM Holdings-B (02142) has announced the signing of a strategic cooperation agreement with China National Pharmaceutical Group (Sinopharm) to create the Sinopharm-HBM Innovation Consortium. This partnership will focus on research and development in the field of innovative biologics, with a strategic emphasis on therapeutic areas such as oncology and immuno-inflammatory diseases.Under the terms of the agreement, the collaboration will span the entire lifecycle of innovative biologic drug development. HBM Holdings-B will leverage its globally leading fully human antibody technology platform, Harbour Mice®, along with its AI-enhanced research capabilities, to jointly conduct the discovery and optimization of candidate antibody molecules with Sinopharm. This includes, but is not limited to, target validation, lead antibody discovery and optimization, antibody configuration design, and antibody engineering.Sinopharm will contribute its expertise in clinical trials, large-scale production, and commercialization. Its responsibilities will include developing commercial-scale process technologies, producing materials for clinical trials, and commercializing the products resulting from the collaboration. Both parties will share research and development costs and product rights according to agreed-upon terms.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148016584","isCrawlerRequest":true}